IDEAYA Biosciences Updates 2026 Strategic Objectives, Plans to Advance Four Registrational Trials
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 11 2026
0mins
Source: Newsfilter
- Advancement of Registrational Trials: IDEAYA plans to advance four registrational trials in 2026, including darovasertib for uveal melanoma, aimed at improving patient prognosis and addressing the lack of FDA-approved therapies.
- Clinical Data Release: Topline PFS data from the darovasertib and crizotinib combination is expected in Q1 2026, and if positive, will support a potential accelerated approval filing in the U.S., enhancing market competitiveness.
- Financial Assurance: As of September 30, 2025, IDEAYA has approximately $1.1 billion in cash and cash equivalents, expected to fund its operating plan into 2030, ensuring ongoing investment in R&D.
- New Drug Development: The company plans to initiate a registrational study for IDE849 targeting small cell lung cancer and neuroendocrine carcinomas by the end of 2026, showcasing its ongoing innovation in precision medicine.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like IDYA with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on IDYA
Wall Street analysts forecast IDYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDYA is 49.86 USD with a low forecast of 30.00 USD and a high forecast of 79.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 33.650
Low
30.00
Averages
49.86
High
79.00
Current: 33.650
Low
30.00
Averages
49.86
High
79.00
About IDYA
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IDEAYA Biosciences Updates 2026 Corporate Objectives at J.P. Morgan Conference
- Pipeline Advancement: In 2025, IDEAYA successfully advanced multiple clinical projects, filing four INDs resulting in nine clinical programs, demonstrating the company's strong execution and readiness in the precision medicine oncology sector.
- Key Trial Plans: In 2026, IDEAYA plans to advance four registrational trials, including IDE849 as a monotherapy for neuroendocrine cancer and darovasertib for both pre-metastatic and metastatic uveal melanoma, aiming to improve patient prognosis and quality of life.
- Funding Assurance: The company expects its cash runway to support operations into 2030, ensuring the continued advancement of key combination therapies in high unmet need cancer areas, thereby enhancing its market competitiveness.
- Strategic Vision: IDEAYA is committed to developing targeted cancer therapies, particularly in the uveal melanoma space where FDA-approved treatments are lacking, showcasing its leadership and innovative potential in precision oncology.
Continue Reading
IDEAYA Biosciences Updates 2026 Strategic Objectives, Plans to Advance Four Registrational Trials
- Advancement of Registrational Trials: IDEAYA plans to advance four registrational trials in 2026, including darovasertib for uveal melanoma, aimed at improving patient prognosis and addressing the lack of FDA-approved therapies.
- Clinical Data Release: Topline PFS data from the darovasertib and crizotinib combination is expected in Q1 2026, and if positive, will support a potential accelerated approval filing in the U.S., enhancing market competitiveness.
- Financial Assurance: As of September 30, 2025, IDEAYA has approximately $1.1 billion in cash and cash equivalents, expected to fund its operating plan into 2030, ensuring ongoing investment in R&D.
- New Drug Development: The company plans to initiate a registrational study for IDE849 targeting small cell lung cancer and neuroendocrine carcinomas by the end of 2026, showcasing its ongoing innovation in precision medicine.
Continue Reading